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Flow synthesis kinetics for lomustine, an anti-
cancer active pharmaceutical ingredient
Samir Diab, † Mateen Raiyat and Dimitrios I. Gerogiorgis *
Continuous flow synthesis of active pharmaceutical ingredients (APIs) can offer access to process
conditions that are otherwise hazardous when operated in batch mode, resulting in improved mixing and
heat transfer, which enables higher yields and greater reaction selectivity. Reaction kinetic parameter
estimation from flow synthesis data is an essential activity for the development of process models for drug
substance manufacturing unit operations and systems, facilitating a reduction of experimental effort and
accelerating development. The flow synthesis of lomustine, an anti-cancer API, in two flow reactors
(carbamylation + nitrosation stages) was recently demonstrated by Jaman et al. (Org. Process Res. Dev.,
2019, 23, 334). In this study, we postulate kinetic rate laws based on hereby proposed reaction mechanisms
presented for the first time in the literature for this API synthesis. We then perform kinetic parameter
regression for the proposed rate laws, on the basis of published data, towards establishing reactor models.
For the carbamylation (irreversible reaction), we compare two candidate reaction rate laws, an overall
third-order rate law (first-order in each reagent) deriving best fit. For the nitrosation, we propose two
substitution reactions on the basis of published mechanisms (a rate-limiting equilibrium step, followed by a
fast irreversible reaction) with very good model fit.
Introduction
Background
The number of people living with cancer and the number of
cancer-related deaths have increased significantly over the last
30 years1,2 (Fig. 1). Global spending on cancer treatment and
prices of anti-cancer drugs have also rapidly increased.3
Although there are many convoluted factors affecting drug
prices,4,5 efficient manufacturing can help to reduce the cost
of production of medicines with societal and economic
impact. Streamlining active pharmaceutical ingredient (API)
manufacturing and accelerating process development can
significantly reduce development costs towards this end.
Flow synthesis of active pharmaceutical ingredients
Flow synthesis demonstrations for a variety of APIs and their
intermediates has received significant attention over the past
decade. Development of flow technology and flow synthetic
routes towards continuous manufacturing has rapidly
increased due to the wide variety of chemical processes
whose performance (productivity, quality, etc.) can be
improved or intensified by switching from batch to
continuous operation. There are several reviews documenting
the rapid development of flow technology for fine chemical
and pharmaceutical products.6–12
Table 1 summarises the various flow synthesis
demonstrations of different anti-cancer APIs in the literature.
However, deciding whether to operate in batch or continuous
mode is non-trivial. For example, reactions with slow kinetics
are better suited to batch operation and the existence of
multiple phases can limit the benefits of operating in one
mode vs. the other.13,14 Moreover, if an existing process route
has acceptable performance with respect to yield, scale,
process time, purity etc., and can be operated safely, then
switching operating mode is not worthwhile. Judicious
process selection and design is imperative for successful
continuous process implementation.15
Reaction modelling to streamline process development
Mathematical modelling and be used to reduce experimental
effort involved in process development and design. Despite
the widespread adoption of modelling approaches in general,
industrial pharmaceutical development is still dominated by
experimental approaches; this is in part due to the fact that
new projects are constantly being begun and terminated
depending on the company's portfolio regarding prioritised
assets, challenges in clinical and process development, etc.
Traditionally, the definition of the process optimum and
the control strategy are supported by design of experiments
(DoE) approaches which are used to construct empirical
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models.24 Despite their value and the advances in high
throughput experimentation technologies,25 they are not
always the most suitable approaches to complex nonlinear
problems typically encountered in pharmaceutical process
systems. Moreover, they are generally resource-intensive.
Mechanistic and first-principles modelling approaches
can provide deeper process understanding during
development and design stages as well as definition of
control strategies. The benefits of developing such models
vary depending on the stage of development, but broadly
include: (a) enhanced process understanding; (b) reducing
experimental effort; (c) aiding process design; (d) sensitivity
analysis; (e) design space elucidation; (f) process
optimisation; (g) aiding scale-up.
Mechanistic modelling approaches are generally well-
developed for reactor design and such models can be the
basis of better-designed processes. In order to develop reactor
models, it is fundamental to develop an understanding of: (a)
reaction mechanisms and kinetics, including rate law
parameters as well as interphase mass transfer, equilibria
and mixing effects; (b) reaction thermodynamics; (c)
dispersion effects and gradients; (d) mass and energy
balances. Without these (either specific knowledge or valid
assumptions therein), a detailed mechanistic understanding
of a reaction remains elusive. Table 2 summarises different
literature demonstrations of reaction kinetic parameter
estimation for flow reaction model development, specifically
for pharmaceutical small molecule synthesis.
This study
One example of an anti-cancer API with demonstrated
continuous flow synthesis (Table 1) is lomustine, used for the
treatment of brain tumours and Hodgkin's lymphoma.21
Between 2013–2019, the cost of lomustine increased from 50
to 768 USD per capsule.48 Herein, we use the available
published reaction data for the lomustine flow synthesis21 in
order to postulate reaction mechanisms for each synthetic
stage (informed by similar reactions in the literature) and
perform kinetic parameter estimation towards reactor
modelling for a drug substance manufacturing system model.
The remainder of this paper is structured as follows. First,
we describe the published flow synthesis process of lomustine,
including the equipment configuration and materials used.21
We then postulate the reaction mechanisms of these steps as a
basis for their proposed rate laws. The kinetic parameter
estimation problem is then mathematically defined. The
regressed kinetic parameters for the proposed rate laws are
then presented with critical discussion of the methodology and
results, followed by the conclusions of this study.
Fig. 1 (a) Global prevalence of cancer, (b) global death rates due to cancer.2
Table 1 Literature demonstrations of flow syntheses of APIs used in cancer treatment
# API Treatment No. reactions Intermediate separations? Yield [%] Capacity [g h−1] Ref.
1 Imatinib Gastrointestinal stromal tumours 6 Y 69 [—] 16
2 Imatinib Gastrointestinal stromal tumours 3 N 58 0.327 17
3 Tasisulam Breast + ovarian cancer 3 N 90 5.200 18, 19
4 Tamoxifen Breast cancer 5 N 84 8.287 20
5 Lomustine Brain tumours
Hodgkin's lymphoma
2 Y 63 0.110 21
6 Prexasertib Acute myeloid leukaemia 3 Y 75–85 0.023 22
7 2-Fluoroadenine Tumour prevention 1 N 82 120 23
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Lomustine flow synthesis
The demonstrated continuous flow synthesis of lomustine
(1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) is performed in
two flow reactors, with an intermediate purification to change
reaction solvents21 – the process flowsheet is shown in Fig. 2.
The overall reaction scheme is shown in Fig. 3. First, the
carbamylation of cyclohexylamine (1, 0.5 mol L−1, 1 equiv.) by
1-chloro-2-isocyanatoethane (2, 1.4 equiv.) in the presence of
triethylamine (TEA, 1 equiv.) occurs in reactor 1 to form 1-(2-
chloroethyl)-3-cyclohexylurea intermediate (3); reactor 1 is
operated at T = 50 °C with tetrahydrofuran (THF) as the
reaction solvent. Reaction data21 is available at residence
times, τ1 = {0, 10, 30, 60} s.
In reactor 2, Int. 3 undergoes nitrosation with tert-butyl
nitrite (4) to form lomustine (API); Int. 3 (1 equiv., 1 mol L−1)
in a mixture of 3.72 : 1 [v/v] acetonitrile/ethanol (MeCN/EtOH)
solvent mixture reacts with 4 (3 equiv. in MeCN) at T = 50 °C
Table 2 Examples of reaction kinetic modelling for API flow syntheses in the literature
# API Application Parameters regressed Kinetic modelling benefits Ref.
1 API (—) Isothermal rate constant, kR Reaction modelling + optimisation,
process selection
26
2 API (—) Arrhenius pre-exponential factor, k0
Activation energy, Ea
Reactor design + scaleup 27
3 Artemether Antimalarial Arrhenius pre-exponential factor, k0
Activation energy, Ea
Rate law
Reaction modelling + optimisation 28





5 Artemisinin Antimalarial Isothermal rate constant, kR Continuous process model simulation
+ optimisation
31, 32
6 Diphenhydramine Antihistamine Isothermal rate constant, kR
Rate law
Continuous process model simulation 33
7 Aziridines Cancer therapy Arrhenius pre-exponential factor, k0
Activation energy, Ea
Reaction modelling + optimisation 34
8 Pyroles Precursor Arrhenius pre-exponential factor, k0
Activation energy, Ea
Rate law
Minimise number of experiments to
characterise kinetic model
35
9 Int. (—) Arrhenius pre-exponential factor, k0
Activation energy, Ea
Reaction modelling + optimisation 36
10 Abemaciclib Anticoagulant Arrhenius pre-exponential factor, k0
Activation energy, Ea
Reaction modelling + optimisation 37
11 Rufinamide Antiepileptic Isothermal rate constant, kR Continuous process simulation 38
12 Thiazolidine Int. Diabetes Arrhenius pre-exponential factor, k0
Activation energy, Ea
Reaction solvent selection 39
13 Glitazone Diabetes Arrhenius pre-exponential factor, k0
Activation energy, Ea
Reaction solvent selection 40
14 Tryptophol Sleep inducing Arrhenius pre-exponential factor, k0
Activation energy, Ea
Reaction modelling + optimisation 41
15 Atropine Nerve agents +
pre-surgical procedures










17 Dolutegravir Int. Anti-HIV Arrhenius pre-exponential factor, k0
Activation energy, Ea
Enable CFD modelling of flow reactor 45
18 Atropine Nerve agents +
pre-surgical procedures
Arrhenius pre-exponential factor, k0
Activation energy, Ea
Model predictive control of continuous
API manufacturing
46
19 API (—) Isothermal rate constant, kR Reaction modelling + optimisation 47
Fig. 2 Process flowsheet for flow synthesis of lomustine.21
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to form API and tert-butanol (tBuOH) by-product. Reaction
data is available at residence times, τ2 = {0, 30, 60, 180, 300,
480} s in the literature demonstration.21 Full details and
properties of these key feed materials, intermediates and
products involved in the flow synthesis of lomustine are
summarised in Table 3.
Reaction mechanisms and kinetic
model equations
Reaction rate and material balances
The following assumptions are made in the reaction kinetic
modelling presented in this study:
(a) Only the considered reactions occur in their
corresponding reactors, i.e., carbamylation in reactor 1,
nitrosation in reactor 2, in the liquid phase only;21
(b) All reactions are isothermal (both reactors operated at
T = 50 °C) as per the demonstrated flow synthesis;21
(c) Ideal mixing is achieved in each reactor, i.e., radial
concentration gradients are negligible, as well as axial
dispersion and temperature gradients (an appropriate
assumption given the scale of the considered experimental
flow synthesis demonstration);21
(d) Constant volumetric flowrates in all reactors, i.e.,
consumption/formation of species due to chemical reaction
does not alter the mixture volume;
(e) Isothermal reactor operation is considered, and the
requisite heat transfer is assumed perfectly efficient, ensured
by appropriate heat transfer media provision and flow (no
heat accumulation);
(f) Reactor operating temperatures are kept safely below
solvent boiling points – this has indeed been confirmed as
per the comparison thereof vs. solvent thermophysical
properties (Table 3);
(g) Precipitation of reagents, intermediates and products
does not occur, on account of the fact that such phenomena
are not reported in the experimental demonstration,
rendering this assumption valid.21
The proposed rate laws and regressed kinetic parameters
should apply to both batch and flow modes of operation given
these assumptions. Upon scale up, care should be taken to
ensure that the intrinsic kinetics still hold; they could
potentially vary due to other reaction rate-limiting barriers such
as heat transfer and gradients within the reactor.
Under the listed assumptions, the general reaction rate
equation is given by eqn (1). Here, rR = rate of reaction R, kR
= isothermal rate constant of reaction R (at T = 50 °C for both
reactors21), NC = total number of species, Ci(τ) =
concentration of species i at residence time τl in reactor l for
a total Nreactor reactors, αi,R = order of species i in reaction R,
Nrxn = total number of reactions, C = vector of species
concentrations. The overall order of reaction, αT,R is the sum
of the individual species' orders, αi,R, (eqn (2)).







Fig. 3 Flow reaction scheme for continuous synthesis of lomustine (API).21
Table 3 Material properties of components used in lomustine flow synthesis (N.A. = not available)
Species Role CAS # Formula MW [g mol−1] Density [g mL−1] Melting point [°C] Boiling point [°C]
1 Reagent 108-91-8 C6H13N 99.17 0.865 −17.7 134.0
2 Reagent 1943-83-5 C5H6ClNO3 163.56 1.237 N.A. 135.0
TEA Reagent/base 121-44-8 C6H15N 101.19 0.726 −114.7 89.3
3 Intermediate 13908-11-7 C9H17ClN2O 204.70 1.110 N.A. N.A.
THF Solvent 109-99-9 C4H8O 72.11 0.889 −108.4 66.0
4 Reagent 463-04-7 C4H9NO2 103.12 0.867 N.A. 62.0
API Product 13010-47-4 C9H16ClN3O2 233.70 1.400 90.0 N.A.
MeCN Solvent 75-05-08 C2H3N 41.05 0.786 −45.0 82.0
EtOH Solvent 64-17-5 C2H6O 46.07 0.789 −114.1 78.4





































































































αi;R ∀R ∈ Nrxn (2)
The material balance of an ideally mixed tubular reactor with
constant volumetric flowrate is described by a system of
ordinary differential equations (ODEs), as per eqn (3). Here,










These equations are now expanded in the context of the




The mechanism of reaction 1 is illustrated in Fig. 4. The
carbamylation (reaction 1) in reactor 1 involves the
interaction between a nucleophile (the lone electron pair on
the nitrogen atom on 1) and an electrophile (the OCN
carbon centre on 2). This then leads to a tetrahedral
intermediate, in which proton transfer then occurs from one
nitrogen atom (which has a positive charge due to the extra
proton) to the other one (which has a free electron from the
opening of the CN bond on 1), resulting in Int. 3.
There is also the possibility that the lone electron pair on
the nitrogen atom of 1 can attack the carbon centre adjacent
to the chlorine atom on 2. This would result in HCl
formation, which would impede the desired reaction of 1
with 2 to form Int. 3. The role of TEA in the reaction is not
explained in the published lomustine flow synthesis,21 but it
is possible that the goal is the prevention of the said effect.
Carbamylations are fast and irreversible.49,50 We compare
two candidate rate laws: (a) first-order in each of 1 and 2 (i.e.,
overall second-order, αT,R = 2) and (b) first-order in each of 1,
2 and TEA (i.e., overall third-order, αT,R = 3). Candidate rate
law (b) is considered as TEA is in 1 : 1 molar equivalent with
reagent 1, which is key in facilitating the carbamylation and
thus the rate law may be dependent on its concentration51 in
addition to the key reagents 1 and 2.
Option (a): r1(τ1, C) = k1C1(τ1)C2(τ1) (4)
Option (b): r1(τ1, C) = k1C1(τ1)C2(τ1)CTEA(τ1) (5)
Expanding eqn (2), the material balances in reactor 1 are thus
described by eqn (6)–(8). Stoichiometric coefficients and
reaction orders for each species are listed in Table 4.
dC1 τ1ð Þ
dτ1
¼ −r1 τ1;Cð Þ (6)
dC2 τ1ð Þ
dτ1
¼ −r1 τ1;Cð Þ (7)
dC3 τ1ð Þ
dτ1
¼ þr1 τ1;Cð Þ (8)
Reactor 2: nitrosation
The overall synthesis of API in reactor 2 is the nitrosation
involving 3 and 4 in aqueous solution. Detailed kinetic rate
law equations of such nitrosation reactions for the
considered system are not published in the literature to the
best of the authors' knowledge. Here, we propose a reaction
mechanism based on other studies for similar nitrosations
and postulate the rate law equations, for which kinetic
parameters are regressed using the available published
experimental data for lomustine synthesis.21
The considered reaction mechanism for the nitrosation of
Int. 3 by 4 involves radical disproportionation of 4 to tBuO˙
(Int. 4a) and ˙NO (Int. 4b), which has been reported to
occur in aqueous conditions.52,53 Thereafter, Int. 4a interacts
with a N–H bond on Int. 3, as illustrated in Fig. 5, forming
tBuOH as well as another radical, which subsequently reacts
with Int. 4b, in order to form the API (lomustine).
The reaction scheme (Fig. 5) shows the tBuO˙ radical
interacting with the N–H bond on the chlorine side of the CO
bond on the Int. 3 molecule as opposed to that adjacent to the
Fig. 4 Carbamylation (reaction 1) mechanism to form Int. 3.
Table 4 Stoichiometric coefficients (v) and reaction orders (α) for
different species in rate equations
Reactor Reaction Species, i
l R 1 2 TEA 3 4 4a 4b API tBuOH
1 1 (Opt. a) vi,1 −1 −1 −1 +1 0 0 0 0 0
αi,1 +1 +1 0 0 0 0 0 0 0
1 (Opt. b) vi,1 −1 −1 −1 +1 0 0 0 0 0
αi,1 +1 +1 +1 0 0 0 0 0 0
2 2f vi,2f 0 0 0 0 −1 +1 +1 0 0
αi,2f 0 0 0 0 +1 0 0 0 0
2r vi,2r 0 0 0 0 +1 −1 −1 0 0
αi,2r 0 0 0 0 0 +1 +1 0 0
3 vi,3 0 0 0 −1 0 0 −1 +1 +1
αi,3 0 0 0 +1 0 0 +1 0 0
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cyclohexyl group. It is possible that the N–H bond adjacent to
the cyclohexyl ring is being stabilised by the said group, leading
to the tBuO˙ radical preferentially interacting with the N–H
bond on the chlorine side of the CO bond. The authors
suggest that the proposed reaction mechanisms be
corroborated with additional data confirming these hypotheses.
The radical formation is considered an equilibrium
reaction with forward and backward reaction rates, r2f and
r2r, respectively, with rate constants, k2f and k2r = k2f/Keq,
respectively, where Keq therein has been defined as the
radical disproportionation equilibrium constant. Reaction 3
is therefore considered an overall irreversible (forward only)
reaction involving Int. 3, Int. 4a and Int. 4b, which proceeds
to form the API (lomustine) as well as tBuOH (a by-product),
as illustrated in the final stage of Fig. 5. The proposed kinetic
rate laws for the foregoing reactions are therefore now
described by eqn (9)–(11).
r2f(τ2, C) = k2fC4(τ2) (9)
r2r τ2;Cð Þ ¼ k2fKeq C4a τ2ð ÞC4b τ2ð Þ (10)
r3(τ2, C) = k3C3(τ2)C4b(τ2) (11)
Expanding from eqn (2), the resulting material balances in
reactor 2 are as per eqn (12)–(14). Stoichiometric coefficients
and reaction orders for reactor 2 are listed in Table 4.
dC3 τ2ð Þ
dτ2
¼ −r3 τ2;Cð Þ (12)
dC4 τ2ð Þ
dτ2
¼ −r2f τ2;Cð Þ þ r2r τ2;Cð Þ (13)
dCAPI τ2ð Þ
dτ2
¼ þr3 τ2;Cð Þ (14)
With the proposed reaction mechanisms, we now formulate
a parameter estimation problem for reaction kinetic
parameter estimation.
Parameter estimation
The regression of reaction kinetic parameters from
experimental data is a parameter estimation problem
described as the minimisation of the sum of square errors in
eqn (15). Here, f = objective function, Nexpt = number of
reaction experiments considered, NC = number of species for
which data is measured and being predicted by the kinetic
model, NP = number of time points at which experimental
data is available, Cmodelp,i, j = model prediction of concentration
of species i and time p in experiment j, Cexptp,i, j is the
corresponding experimental value, τp, j = time p in experiment










Cmodelp;i; j τp; j; θ
 
–C exptp;i; j τp; j
 




For each reaction, Nexpt = 1. In reactor 1, NC = 3 (species i =
reagent 1, reagent 2, Int. 3), NP = 4; in reactor 2, NC = 3 (species
i = 3, reagent 4, API), NP = 6. For reaction 1 occurring in reactor
1, the parameter vector in eqn (15) is θ = k1. For Reactions 2 + 3
in reactor 2, the parameter vector in eqn (15) is θ = [k2f, Keq, k3].
The model equations and parameter estimation problem
are coded in MATLAB. The system of ODEs is solved using
ode15s (stiff ODE solver54) and the parameter estimation
problem is solved using lsqnonlin (Levenberg–Marquardt
algorithm,55,56 default tolerance = 10−6). Reactor 1 is
simulated for a total τ = 60 s and reactor 2 is simulated for a
total τ = 480 s, chosen as the maximum time at which
reaction data is available in the experimental
demonstrations.21 All modelling is performed on an Intel®
Core™ i-78665 CPU @ 1.90 GHz processor with 16.0 GB of
RAM. In all cases, a single simulation took <1 s and the
parameter estimation problem was solved in <10 s.
Results and discussion
Carbamylation (reaction 1)
The model fits for both candidate rate laws (options a and b)
for reaction 1 in reactor 1 are shown in Fig. 6; parameter fits
are summarised in Table 5 along with fitting confidence
interval (CIs) and the corresponding coefficients of
determination (R2) for each concentration profile. It can be
seen a better fit is obtained for option (b), however option (a)
still provides good fit, albeit with lower confidence.
The yield of Int. 3 in reaction 1 is calculated as the ratio
of molar concentration of Int. 3 at the end of the reaction vs.
the initial molar concentration of limiting reagent (= Reagent
1). The assumed rate law thus also results in different yields
Fig. 5 Overall nitrosation reaction mechanism in reactor 2 to form API.52
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of Int. 3 vs. residence time, shown in Fig. 7; option (a)
overpredicts the Int. 3 concentration (see model vs. data in
Fig. 6a) compared to option (b), which fits better.
Corroboration with additional data is required to confidently
distinguish between the options.
Nitrosation (reactions 2 + 3)
The model fit for the considered reaction mechanism/rate
laws for the reactions occurring in reactor 2 are shown in
Fig. 8. Parameter fits are summarised in Table 6. The quality
of fit is very high for the considered rate laws, however
confidence in the parameter fits (= CI) is lower than for
reaction 1. The yield of API from reactions 2 + 3 is calculated
as the ratio of product (= API) obtained at the end of the
reaction vs. the initial concentration of limiting reagent (= Int.
3). The corresponding API yield profile is shown in Fig. 9.
As per our hypothesis, the equilibrium constant of
reaction 2 is low, i.e., the equilibrium is far to the left and
thus reaction 2 is rate limiting with respect to API formation.
Reaction 3 then proceeds very fast, as shown by the high
value of rate constant k3. This observed behaviour of a rate-
limiting equilibrium step followed by a fast reaction is often
observed in organic syntheses,57,58 including nitrosation, as
is occurring in reactions 2 + 3.59,60
Discussion
The proposed reaction mechanisms and rate laws fit the
available data for each reaction very well; corroboration of
the proposed rate laws can be accomplished by means of
additional experimental effort towards data acquisition,
which should ideally address: (a) spectroscopic identification
of relevant intermediates for proposed reaction mechanisms,
(b) high-resolution dynamic concentration measurements
(especially at the onset of reactions, during which
concentration gradients are steepest), (c) parametric (e.g. feed
flowrates, reactor temperatures) variation. Obtaining such
augmented datasets is beyond the scope of our kinetic
analysis study; nevertheless, such an effort can certainly
enhance our understanding of the reaction mechanisms for
this particular API synthetic route.
A kinetic model is most often based on an assumed reaction
mechanism whose rate equations are then to be validated via
experimental data, possibly via similar reaction literature
Fig. 6 Kinetic parameter fit for reaction 1. (a) Overall second-order
rate law, (b) overall third-order rate law.
Fig. 7 Int. 3 yield profile for different reaction 1 rate law assumptions.
Table 6 Regressed kinetic parameter values and model fit quality for nitrosation reaction (reactions 2 + 3)
Reaction Parameter θ Value 95% CI Units
Coefficient of determination (R2)
3 4 API
2 k2f 0.5074 ±19.00% [s
−1] 0.9558 0.9715 0.9709
Keq 1.1798 × 10
−5 ±16.70% [mol L−1]
3 k3 100.1360 ±16.50% [L mol
−1 s−1]
Table 5 Regressed kinetic parameter values and model fit quality for carbamylation (reaction 1)
Parameter θ Value 95% CI Units
Coefficient of determination (R2)
1 2 3
k1 (Opt. a) 0.1906 ±16.96% [L mol
−1 s−1] 0.9820 0.9820 0.9820
k1 (Opt. b) 0.9024 ±6.75% [L
2 mol−2 s−1] 0.9988 0.9988 0.9988
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precedents. This validation does not ensure uniqueness or
proof of the postulate, but has predictive value. The quality of
fit for model parameters (best assessed by confidence intervals)
strongly depends on data quality and quantity, and can
indicate whether the assumed mechanism (thus: model
structure) is correct, or if an alternative pathway may actually
be occurring (assuming the parameter estimation algorithm
and solver settings are suitably chosen to safeguard against
local minimisation entrapment possibility).
Computational chemistry complements experiments in
order to elucidate complex reaction phenomena. Density
functional theory (DFT) is an established and efficient
methodology61 for studying and analysing mechanisms
related to stereoselectivity,62 organocatalysis,63 and provides
valuable assistance to spectroscopic64 and other relevant
investigations. A DFT approach may provide additional
insight, but is beyond the scope of our present study. Various
hurdles still remain to allow for its wider applicability and
use, including the issue of successful predictions of
transition structure geometry65 (which are key to the reaction
mechanisms proposed in this study), the selection of
appropriate functionals66 and the hazard of errors in kinetic
parameter estimations67 (also important in this study). It
would be an exciting prospect for this kinetic parameter
estimation study to motivate DFT analyses.
Conclusions
The demonstrated flow synthesis of lomustine and available
reaction data were used to postulate candidate rate laws based
on proposed reaction mechanisms for each synthesis step. For
the carbamylation (irreversible reaction), we compare two
candidate reaction rate laws, with an overall third-order rate law
(first-order in each reagent) showing the best fit. For the
nitrosation (in the first reactor), we propose two substitution
reactions (one rate-limiting equilibrium step, one fast
irreversible step) with very good model fit vs. published
experimental data. Corroboration of the proposed mechanisms
with computational chemistry (e.g. DFT) methods and/or
additional experimentation can enhance understanding of
the reaction mechanisms for this API synthetic route. The
presented kinetic model can accelerate continuous reactor
design, scale-up and optimisation of lomustine production.
Nomenclature
Acronyms
API Active pharmaceutical ingredient
CI Confidence interval
DFT Density functional theory
DoE Design of experiments
















C Concentration [mol L−1]
C Vector of species concentrations [mol−1]
Ea Activation energy [J mol
−1]
f Parameter estimation objective function [−]
Keq Equilibrium constant [mol L
−1]
k0 Pre-exponential factor [L
αT−1 molαT−1 s−1]
kR Isothermal rate constant of reaction R
[LαT−1 molαT−1 s−1]
MW Molecular weight [g mol−1]
NC Number of components [−]
Nexpt Number of experiments [−]
NP Number of data points [−]
Nreactor Number of reactors [−]
Nrxn Number of reactions [−]
R2 Coefficient of determination [−]
rR Rate of reaction R [mol L
−1 s−1]
Fig. 8 Kinetic parameter fit for reactions 2 and 3 in reactor 2.
Fig. 9 API yield profile in reactor 2.
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T Temperature [°C]
vi,R Stoichiometric coefficient of species i in reaction R [−]
Greek letters.
αi,R Reaction order of species i in reaction R [−]
αT,R Overall order of reaction R [−]
τ Residence time [s]
θ Parameter vector
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